These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 21985373)

  • 21. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
    Eguren-Santamaria I; Fernández de Piérola E; Camps G; Martín-Muñoz P; Campos M; Cuculescu D; Aguilera-Buenosvinos I; Rodríguez López I; Salido-Vallejo R; Alexandru R; De Andrea CE; Álvarez-Gigli L; Berraondo P; Melero I; Sanmamed MF
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39244214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.
    Ehx G; Somja J; Warnatz HJ; Ritacco C; Hannon M; Delens L; Fransolet G; Delvenne P; Muller J; Beguin Y; Lehrach H; Belle L; Humblet-Baron S; Baron F
    Front Immunol; 2018; 9():1943. PubMed ID: 30214443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human T cells depend on functional calcineurin, tumour necrosis factor-α and CD80/CD86 for expansion and activation in mice.
    Søndergaard H; Kvist PH; Haase C
    Clin Exp Immunol; 2013 May; 172(2):300-10. PubMed ID: 23574326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice.
    Adhikary SR; Geraghty NJ; Cuthbertson P; Sluyter R; Watson D
    Purinergic Signal; 2019 Jun; 15(2):177-192. PubMed ID: 31001750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease.
    Bruck F; Belle L; Lechanteur C; de Leval L; Hannon M; Dubois S; Castermans E; Humblet-Baron S; Rahmouni S; Beguin Y; Briquet A; Baron F
    Cytotherapy; 2013 Mar; 15(3):267-79. PubMed ID: 23265769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Simple Mouse Model for the Study of Human Immunodeficiency Virus.
    Kim KC; Choi BS; Kim KC; Park KH; Lee HJ; Cho YK; Kim SI; Kim SS; Oh YK; Kim YB
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):194-202. PubMed ID: 26564392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Natural Killer Cells in Intravenous Immunoglobulin-Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg(-/-) (NSG) Mice.
    Gregoire-Gauthier J; Fontaine F; Benchimol L; Nicoletti S; Selleri S; Dieng MM; Haddad E
    Biol Blood Marrow Transplant; 2015 May; 21(5):821-8. PubMed ID: 25596424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells].
    Gao L; Wang JM; Xie LN; Zhou H; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):87-91. PubMed ID: 18681307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
    Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
    Cuthbertson P; Geraghty NJ; Adhikary SR; Casolin S; Watson D; Sluyter R
    Clin Sci (Lond); 2021 Feb; 135(3):495-513. PubMed ID: 33463682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxazolone and ethanol induce colitis in non-obese diabetic-severe combined immunodeficiency interleukin-2Rγ(null) mice engrafted with human peripheral blood mononuclear cells.
    Nolte T; Zadeh-Khorasani M; Safarov O; Rueff F; Gülberg V; Herbach N; Wollenberg A; Mueller T; Siebeck M; Wolf E; Gropp R
    Clin Exp Immunol; 2013 May; 172(2):349-62. PubMed ID: 23574330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
    van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
    Front Immunol; 2018; 9():3016. PubMed ID: 30619360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8
    Matsumoto R; Enzhi Y; Takeda K; Morimoto K; Yogo K; Harada M; Tokushige K; Maehara Y; Hirota S; Kojima Y; Ito M; Sougawa N; Miyagawa S; Sawa Y; Okumura K; Uchida K
    J Heart Lung Transplant; 2024 Aug; 43(8):1348-1357. PubMed ID: 38657776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
    Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
    Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
    J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.
    Hannon M; Lechanteur C; Lucas S; Somja J; Seidel L; Belle L; Bruck F; Baudoux E; Giet O; Chantillon AM; Delvenne P; Drion P; Beguin Y; Humblet-Baron S; Baron F
    Transfusion; 2014 Feb; 54(2):353-63. PubMed ID: 23772685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
    Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
    Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
    Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
    Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.